Special Issue

Drug Metabolism and New Drug Development for Cancers

Message from the Guest Editors

Cancer is one of the top causes of death worldwide. However, medical sciences do not remain indifferent and the race is on, the primary goal of which is to help patients through the development of new anticancer drugs and treatments. Understanding metabolic pathways and developing new molecules and formulations for drug delivery are only some of the possible weapons in this unequal fight. The path from developing an active ingredient to implementing the drug into clinical practice is long and involves the work of many specialists. This Special Issue aims to publish original articles and review articles on the following topics:

- The biochemistry of anticancer molecules.
- The impact of anticancer drugs/substances on metabolism.
- Natural compounds/extracts and plant screening for antineoplastic activity metabolites.
- Studies in pharmaceutical chemistry: drug structure and activity relationships or the development of new molecules.
- Developing new delivery methods for known substances, for example, formulating new nanoforms such as liposomes, micelles, nanospheres, etc.

Guest Editors

Prof. Dr. Anna Jelińska


Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 60-780 Poznan, Poland

Dr. Szymon Tomczak

Department of Pharmaceutical Chemistry, Poznan University of Medical Sciences, 60-780 Poznan, Poland

Deadline for manuscript submissions

31 August 2025



an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



mdpi.com/si/193465

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/ metabolites





Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7 CiteScore 6.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo

Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).

